Location History:
- Berkeley, CA (US) (2022)
- Kensington, CA (US) (2021 - 2023)
- Oakland, CA (US) (2024)
Company Filing History:
7 out of 15,502 
2 out of 289 
Years Active: 2021-2025
Title: The Innovative Contributions of Rebecca J Abergel
Introduction
Rebecca J Abergel is a prominent inventor based in Kensington, CA (US). She has made significant contributions to the field of pharmaceutical formulations and radionuclide delivery systems. With a total of 7 patents to her name, her work has had a profound impact on nuclear medicine and chelation therapy.
Latest Patents
Among her latest patents, one notable invention is the "Formulations of hydroxypyridonate actinide/lanthanide decorporation agents." This patent provides pharmaceutical formulations that comprise a 1,2-HOPO chelating agent and/or a 3,2-HOPO chelating agent. Another significant patent is the "Chelating platform for delivery of radionuclides," which describes siderocalin-metal chelator combinations that bind metallic radioisotopes used in nuclear medicine with high affinity. These combinations can be utilized for imaging and therapeutic purposes, showcasing her innovative approach to medical challenges.
Career Highlights
Rebecca has worked with esteemed institutions such as the University of California and Fred Hutchinson Cancer Center. Her career is marked by a commitment to advancing medical science through her inventions and research.
Collaborations
Throughout her career, Rebecca has collaborated with notable professionals, including Gauthier J P Deblonde and Roland K Strong. These collaborations have further enriched her work and contributed to her success in the field.
Conclusion
Rebecca J Abergel's innovative contributions to the fields of chelation therapy and nuclear medicine highlight her role as a leading inventor. Her patents and collaborations reflect her dedication to improving medical treatments and advancing scientific knowledge.